Keratoconus Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Clinical Trials by DelveInsight | CooperVision, Optik Seis, SAFILENS S.R.L, Novartis, CIBA VISION, Menicon, Bausch & Lomb

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Keratoconus pipeline constitutes 3+ key companies continuously working towards developing 3+ Keratoconus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Keratoconus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Keratoconus Market.

The Keratoconus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Keratoconus Pipeline Report: https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Keratoconus treatment therapies with a considerable amount of success over the years.
• Keratoconus companies working in the treatment market are Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others, are developing therapies for the Keratoconus treatment
• Emerging Keratoconus therapies in the different phases of clinical trials are- Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others are expected to have a significant impact on the Keratoconus market in the coming years.
• In October 2024, Glaukos Corporation (NYSE: GKOS), a pharmaceutical and medical technology company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, announced positive results from the second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on). This next-generation corneal cross-linking iLink therapy for keratoconus met its pre-specified primary efficacy endpoint, showing a clinically meaningful and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months compared to the sham/placebo-controlled group. Kmax, an FDA-accepted primary efficacy metric for keratoconus trials, measures the steepest corneal curvature using topography, with higher Kmax values indicating corneal steepening and disease progression.

Keratoconus Overview
Keratoconus is a progressive eye disease in which the normally round, dome-shaped cornea thins and begins to bulge into a cone-like shape. This cone shape deflects light as it enters the eye, causing distorted vision.

Get a Free Sample PDF Report to know more about Keratoconus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/keratoconus-pipeline-insight

Emerging Keratoconus Drugs Under Different Phases of Clinical Development Include:
• Riboflavin 5'-Phosphate: Glaukos Corporation
• IVMED-80: iVeena Delivery Systems
• Dextenza: Ocular Therapeutix, Inc.

Keratoconus Route of Administration
Keratoconus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Keratoconus Molecule Type
Keratoconus Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Keratoconus Pipeline Therapeutics Assessment
• Keratoconus Assessment by Product Type
• Keratoconus By Stage and Product Type
• Keratoconus Assessment by Route of Administration
• Keratoconus By Stage and Route of Administration
• Keratoconus Assessment by Molecule Type
• Keratoconus by Stage and Molecule Type

DelveInsight's Keratoconus Report covers around 3v+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Keratoconus product details are provided in the report. Download the Keratoconus pipeline report to learn more about the emerging Keratoconus therapies
https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Keratoconus Therapeutics Market include:
Key companies developing therapies for Keratoconus are - CooperVision, Optik Seis, SAFILENS S.R.L, Novartis AG, CIBA VISION, Menicon Co. Ltd, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care Inc, HOYA Vision Care, and others.

Keratoconus Pipeline Analysis:
The Keratoconus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Keratoconus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Keratoconus Treatment.
• Keratoconus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Keratoconus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Keratoconus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Keratoconus drugs and therapies
https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Keratoconus Pipeline Market Strengths
• Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight

Keratoconus Pipeline Market Opportunities
• There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market.

Scope of Keratoconus Pipeline Drug Insight
• Coverage: Global
• Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others
• Key Keratoconus Therapies: Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others
• Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies
• Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers

Request for Sample PDF Report for Keratoconus Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Keratoconus Report Introduction
2. Keratoconus Executive Summary
3. Keratoconus Overview
4. Keratoconus- Analytical Perspective In-depth Commercial Assessment
5. Keratoconus Pipeline Therapeutics
6. Keratoconus Late Stage Products (Phase II/III)
7. Keratoconus Mid Stage Products (Phase II)
8. Keratoconus Early Stage Products (Phase I)
9. Keratoconus Preclinical Stage Products
10. Keratoconus Therapeutics Assessment
11. Keratoconus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Keratoconus Key Companies
14. Keratoconus Key Products
15. Keratoconus Unmet Needs
16 . Keratoconus Market Drivers and Barriers
17. Keratoconus Future Perspectives and Conclusion
18. Keratoconus Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Keratoconus Market https://www.delveinsight.com/report-store/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Keratoconus Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Keratoconus Epidemiology https://www.delveinsight.com/report-store/keratoconus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Keratoconus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.